GlassScriptPhysician profile
Sushil K Singhi
NPI 1457304628
$6,386.64
in general payments reported to CMS, 2019-2025
29 companies · $645 in 2025
The $645 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,161 · 2020: $102 · 2021: $586 · 2022: $290 · 2023: $1,633 · 2024: $970 · 2025: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,641 · Travel and Lodging: $607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,640.52 |
| Travel and Lodging | $607.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $1,805.62 | 2019 | |
| Inspire Medical Systems, INC. | $988.16 | 2021-2025 | Inspire |
| Janssen Research & Development, LLC | $897.24 | 2023 | |
| Abiomed | $307.44 | 2021-2024 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $228.90 | 2021-2023 | Jardiance |
| Edwards Lifesciences Corporation | $227.11 | 2019-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Astrazeneca Pharmaceuticals LP | $211.57 | 2021 | |
| Boston Scientific Corporation | $184.48 | 2019-2025 | Avvigo Guidance System, Varithena Administration Pack |
| Novo Nordisk INC | $181.99 | 2024-2025 | Ozempic |
| E.R. Squibb & Sons, L.L.C. | $164.85 | 2019-2024 | Camzyos |
| Atricure, INC. | $149.86 | 2021-2023 | |
| Amarin Pharma, INC. | $125.00 | 2019 | |
| Biotronik INC. | $124.95 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $121.75 | 2025 | |
| Janssen Pharmaceuticals, INC | $111.93 | 2022-2024 | Xarelto |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $111.48 | 2025 | |
| Abbott Laboratories | $109.57 | 2022-2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Amgen INC. | $66.13 | 2019-2023 | Repatha |
| Tactile Systems Technology INC | $48.75 | 2021-2023 | Flexitouch Plus, Entre Plus |
| Lexicon Pharmaceuticals, INC. | $46.77 | 2024 | |
| Kestra Medical Technology Services, INC. | $33.43 | 2024 | Assure Wcd |
| Pfizer INC. | $29.49 | 2023-2024 | |
| Cvrx, INC. | $21.48 | 2025 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $17.36 | 2019 | |
| Merck Sharp & Dohme LLC | $17.15 | 2021 | |
| Cleerly, INC. | $15.90 | 2024 | Cleerly Ischemia, Cleerly Labs |
| Sanofi-Aventis U.S. LLC | $14.74 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $12.72 | 2019 | |
| Gilead Sciences, INC. | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sushil Singhi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.